{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:56:38Z","timestamp":1778590598153,"version":"3.51.4"},"reference-count":28,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eurotron International doo","award":["014-28\/70-15"],"award-info":[{"award-number":["014-28\/70-15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Among malignant diseases which develop during childhood, hematological cancers, such as leukemias and lymphomas, are the most common. Outcomes have greatly improved due to the refinement of multiagent chemotherapy regimens that include enhanced asparaginase therapy. In this study, we aimed to evaluate our experiences related to the analytical and clinical significance of determining l-Asparaginase activity. Methods: Since 2016, the Laboratory of the Children\u2019s Hospital Zagreb has routinely measured l-Asparaginase activity and to date, has measured more than 280 examples of activity in a total of 57 children with hematological malignancy treated at the Pediatric Oncology Department of the Children\u2019s Hospital Zagreb. Three asparaginase products were available: native E. colil-Asparaginase; a pegylated form of this enzyme; and a native product from Erwinia chrysanthemi. A retrospective data analysis was performed. Results: Out of the fifty-seven children, seven had an allergic reaction (12.3%), five (8.8%) had silent inactivation, and seven (12.3%) developed acute pancreatitis. Allergic reactions and silent inactivation were more common in children treated with native E. colil-Asparaginase, while pancreatitis was more common in children treated with the pegylated form. Conclusions: The monitoring of l-Asparaginase activity may help to optimize therapy by identifying patients with \u2018silent inactivation\u2019, and\/or by dose correction when l-Asparaginase activity is too high (slow elimination).<\/jats:p>","DOI":"10.3390\/diagnostics14060623","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:02:39Z","timestamp":1710504159000},"page":"623","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Determination of l-Asparaginase Activity and Its Therapeutic Monitoring in Children with Hematological Malignancies in a Single Croatian Center"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-4034","authenticated-orcid":false,"given":"Jasna","family":"Lenicek Krleza","sequence":"first","affiliation":[{"name":"Department of Laboratory Diagnostics, Children\u2019s Hospital Zagreb, 10000 Zagreb, Croatia"},{"name":"Department of Basic Medical Chemistry and Biochemistry, University Studies in Nursing, Universitas Studiorum Catholica Croatica, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Katusic Bojanac","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Centre of Excellence for Reproductive and Regenerative Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordana","family":"Jakovljevic","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Children\u2019s Hospital Zagreb, 10000 Zagreb, Croatia"},{"name":"Department of Pediatrics, Faculty of Medicine, University of Osijek, 31000 Osijek, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"ref_1","unstructured":"(2024, March 09). Croatian National Cancer Registry: Cancer Incidence in Croatia 2020. Croatian Institute of Public Health Bilten No. 45, Zagreb. Available online: https:\/\/www.hzjz.hr\/wp-content\/uploads\/2022\/11\/Bilten-Incidencija-raka-u-Hrvatskoj-2020.-godine.pdf."},{"key":"ref_2","unstructured":"(2024, March 09). Croatian National Cancer Registry: Data from the Croatian National Cancer Registry for 2021, Zagreb. (In Croatian)."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.22.01760","article-title":"Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-M\u00fcnster 2009 Trial","volume":"41","author":"Campbell","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): Analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","article-title":"Asparaginase-associated toxicity in children with acute lymphoblastic leukemia","volume":"57","author":"Hijiyaa","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/pbc.24420","article-title":"Children\u2019s Oncology Group\u2019s 2013 blueprint for research: Acute lymphoblastic leukemia","volume":"60","author":"Hunger","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","article-title":"Tolerability and efficacy of l-Asparaginase therapy in pediatric patients with acute lymphoblastic leukemia","volume":"32","author":"Raetz","year":"2010","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of l-Asparaginase in childhood ALL","volume":"28","author":"Muller","year":"1998","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1517\/14712598.2012.718327","article-title":"Erwinia asparaginase in pediatric acute lymphoblastic leukemia","volume":"12","author":"Salzer","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10238-008-0026-9","article-title":"The cross-reactivity of anti-asparaginase antibodies against different l-Asparaginase preparations","volume":"9","author":"Gach","year":"2009","journal-title":"Clin. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2013-01-480822","article-title":"Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: A report from the Children\u2019s Oncology Group","volume":"122","author":"Salzer","year":"2013","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3109\/10428194.2014.1003056","article-title":"Asparaginase pharmacokinetics and implications of therapeutic drug monitoring","volume":"56","author":"Asselin","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-1-4615-4811-9_69","article-title":"The three asparaginases: Comparative pharmacology and optimal use in childhood leukemia","volume":"457","author":"Asselin","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_15","first-page":"299","article-title":"Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL)","volume":"29","author":"Avramis","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"Vrooman","year":"2016","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEG asparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children\u2019s Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2019.242289","article-title":"Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: A population pharmacokinetic model","volume":"106","author":"Kloos","year":"2020","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0003-2697(02)00232-4","article-title":"Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-Asparaginase in human serum","volume":"309","author":"Lanvers","year":"2002","journal-title":"Anal Biochem."},{"key":"ref_21","unstructured":"van Maanen, C., Stigter, R.I., van der Sluis, I.M., and Beishuizen, A. (2014). Assay for the Measurement of Asparaginase in Children with Acute Lymphoblastic Leukemia, Erasmus MC. Ver. 1.2."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","article-title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017","volume":"9","author":"Dong","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"M\u00fcller, J., Egyed, P., Erdelyi, D., Kovacs, K., Mudra, K., Szabo, S., Egyed, B., and Gabor, K. (2023). Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases. Children, 10.","DOI":"10.3390\/children10071160"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e5300","DOI":"10.1097\/MD.0000000000005300","article-title":"A childhood acute lymphoblastic leukemia genome-wide association study identifies novel sex-specific risk variants","volume":"95","author":"Singh","year":"2016","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"a034819","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and Etiology of Leukemia and Lymphoma","volume":"10","author":"Bispo","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1188\/17.CJON.E248-E259","article-title":"Asparaginase Toxicities: Identification and Management in Patients with Acute Lymphoblastic Leukemia. Asparaginase Toxicities: Identification and Management in Patients with Acute Lymphoblastic Leukemia","volume":"21","author":"Huynh","year":"2017","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/FTD.0000000000000727","article-title":"Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children with Acute Lymphoblastic Leukemia Treated with PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study","volume":"42","author":"Gerss","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/6\/623\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:14:04Z","timestamp":1760105644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/6\/623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["diagnostics14060623"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14060623","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}